Does a GLP-1 cause gastroparesis?

Across FDA reports

Which products have FDA reports for impaired gastric emptying

One FDA term across eight brands. Two rows contain measured shares; the others only show that the term fell below each product’s cut-off.

A dashed row is not a zero. The snapshot keeps each product’s 25 most-reported terms, so a term missing from that list was either never reported or reported and ranked 26th. All this page can prove is that it sits at or below the 25th, and that is what the row says.

Every share above is a share of that product’s own reports. It is never a share of the people who took it, because nobody knows how many that is. Two products can differ here for reasons that have nothing to do with either drug.

Both measured rows are the same molecule

Ozempic and Rybelsus are the only brands whose stored terms include it, and both are semaglutide. The tirzepatide and liraglutide products all sit below their own ceilings.

Wegovy is the row that stops this being a clean molecule story. It is semaglutide too, and its share is below its cut-off. So the pattern is not simply semaglutide against everything else.

Ozempic and Rybelsus have something else in common besides the molecule. Both are diabetes products, prescribed for years longer than the weight brands. Time on the market is one of the strongest drivers of report volume there is.

The same ruler, held against something else

Vomiting is included as a check because it appears on every label and in FDA reports for most brands. It helps show whether differences are specific to one term or affect the data more broadly.

Why litigation has to be ruled out first

Lawsuits generate reports. A law firm advertises for people who took a named drug and had a named problem. Reports of that problem then go up, and the drug did not change.

The stomach paralysis claims are public, they name semaglutide products, and they run through the years this snapshot covers. A reading of these two rows that skips over that tells a story about biology. A simpler explanation is sitting in plain sight.

The reports cannot separate a drug effect from reporting driven by lawsuits. Both the number and that important limitation have to be considered together.

What the labels say about it

The labels describe delayed stomach emptying as part of how the drug acts, not as a surprise. Several also carry warnings about food left in the stomach before a procedure with anesthesia.

So the mechanism is not in question and never was. The open question is whether it turns into a lasting condition in some people. A count of reports is not the study that answers it.

This section summarizes reports people filed. The label guides show what the FDA-approved prescribing information lists. The two answer different questions and they often disagree, which is the most useful thing about having both.

What this page does and does not establish

This is the page where the distance between the number and the headline is widest, so it is written out in full.

Common questions

Where to go next

This page is one question asked of one snapshot. The pages below answer the neighboring ones from the labels and the trials, which is a different kind of evidence.

• Symptom questionsThe same stomach and gut questions asked of the labels.
• Compound guidesThe reaction table each label publishes.
• The dosing-error studyHow to interpret FDA reports without treating them as incidence rates.

Every question in this section is listed on the report-stream questions index.

Read this before quoting anything above

These are counts of reports filed with the FDA, not rates. Nobody knows how many people took the drug and did not file a report, and a report is not a finding that the drug caused what was reported.

• There is no denominator. FAERS counts reports that were filed. It does not count the people who took the drug, so there is no bottom half to the fraction. Any figure on this page that looks like a percentage is a share of this drug’s reports — never a share of the people who took it.
• A report is not proof the drug did it. FDA does not require a reporter to establish cause. A report says somebody noticed something and thought the drug was worth naming. Some of these events were caused by the drug, some were caused by the illness it was prescribed for, and some were coincidence — FAERS does not separate them.
• A bigger number can just mean a more-prescribed drug. More reports can simply mean that more people use the drug, that it is newer, or that it receives more news and legal attention. Raw report totals do not tell you which drug is safer.
• The same event can be counted twice. One event can reach FAERS through more than one channel — the patient, the prescriber and the manufacturer can all file. FDA does not guarantee that the public files are de-duplicated.
• FDA’s own words. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
• Retrieved 2026-08-17 from https://api.fda.gov/drug/event.json · FDA data last updated 2026-07-30 · license https://open.fda.gov/license/

How everything on this site is sourced →